5 Key Takeaways

• 1

  The phase 3 program for ixo-vec in neovascular AMD includes ARTEMIS and AQUARIUS studies evaluating its long-term efficacy.

• 2

  Ixo-vec aims to provide continuous aflibercept production after a single injection, reducing treatment burden for nAMD patients.

• 3

  Previous trials, OPTIC and LUNA, showed sustained aflibercept expression and stable visual acuity with reduced injection frequency.

• 4

  Safety findings indicated no severe adverse events, with mild inflammation manageable through local corticosteroids.

• 5

  Data from ARTEMIS is expected in early 2027, with AQUARIUS results anticipated later that year.